GURU.Markets stock price, segment price, and overall market index valuation
The company's share price PMN
ProMIS Neurosciences is a biotech company developing drugs to treat neurodegenerative diseases such as Alzheimer's. Its stock price is highly volatile, betting on the success of its unique scientific approach in one of the most complex areas of medicine.
Share prices of companies in the market segment - Pharma neurology
ProMIS Neurosciences is a Canadian biopharmaceutical company developing targeted therapies for the treatment of neurodegenerative diseases such as Alzheimer's. We have classified it in the Pharma: Neuroscience category. The chart below shows how the market is evaluating new approaches to treating these diseases.
Broad Market Index - GURU.Markets
ProMIS Neurosciences is a biopharmaceutical company developing targeted therapies for the treatment of neurodegenerative diseases such as Alzheimer's. It is a component of the GURU.Markets index, and the chart below shows how its stock compares to the broader market.
Change in the price of a company, segment, and market as a whole per day
PMN - Daily change in the company's share price PMN
For ProMIS Neurosciences, Inc., which develops drugs for neurodegenerative diseases, daily price change is a measure of enormous volatility. This metric reflects extreme sensitivity to clinical trial data and is key to risk assessment.
Daily change in the price of a set of shares in a market segment - Pharma neurology
ProMIS Neurosciences, Inc. is a biotech company. This chart shows the extreme volatility of the sector. Comparison with PMN, which focuses on treating neurodegenerative diseases, helps to assess it as a high-risk asset.
Daily change in the price of a broad market stock, index - GURU.Markets
ProMIS Neurosciences is a biotech company working on treatments for neurological diseases such as Alzheimer's. Its shares are driven by news of clinical trials. This high volatility is a significant component of the overall "noise" and dynamics of the stock market.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization PMN
ProMIS Neurosciences' year-to-date performance is a story of developing a new approach to treating Alzheimer's disease. Its 12-month market cap is entirely dependent on data from preclinical and early clinical trials of its antibody, which targets toxic beta-amyloid oligomers, one of the most promising avenues in this field.
Annual dynamics of market capitalization of the market segment - Pharma neurology
As an early-stage biotech company, ProMIS is a high-risk bet on science. Its performance is completely disconnected from the sector and depends on news about clinical trials of its Alzheimer's drugs. Its stock price will reflect the speculative faith of investors.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
ProMIS Neurosciences is a clinical-stage biotech whose fate depends on scientific breakthroughs, not the state of the economy. Its stock price reflects investor hopes for the success of new drug trials. The company's chart exists in a world of its own, where the main events are data releases.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization PMN
ProMIS Neurosciences is a biotech company developing drugs for the treatment of neurodegenerative diseases. Its monthly performance is entirely dependent on progress in its clinical trials. News of its lead candidate's clinical trial results is the main driver.
Monthly dynamics of market capitalization of the market segment - Pharma neurology
This chart reflects the dynamics of the biotech sector, particularly in the field of neurodegenerative diseases. For ProMIS, an early-stage company, this is the backdrop. Its volatile movements demonstrate how investor expectations surrounding breakthroughs in Alzheimer's treatment are impacting the entire industry.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
ProMIS Neurosciences is a biotech company developing antibodies to treat neurodegenerative diseases such as Alzheimer's. Its value depends on the success of clinical trials. The overall market price has little impact on ProMIS; its shares are driven by scientific news, which can cause sharp movements counter to any market trend.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization PMN
ProMIS Neurosciences, which is developing therapies against misfolded proteins that cause Alzheimer's disease, is extremely sensitive to scientific news. Its weekly stock price is a strong reaction to any preclinical or clinical trial data that might offer hope in this complex and competitive field.
Weekly dynamics of market capitalization of the market segment - Pharma neurology
ProMIS Neurosciences operates in the highly competitive Alzheimer's disease treatment sector, where investor sentiment drives broad ripples. Any significant success or failure in the industry impacts everyone's risk appetite. The chart will reveal whether PMN is following the mainstream biotech speculation or whether its unique approach sets it apart.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
ProMIS Neurosciences, as a biotech company, often ignores broader market trends. Its fate depends not on GDP or inflation, but on the results of clinical trials. The chart below clearly demonstrates how PMN shares can rise or fall on their own news, while the overall market moves in a different direction.
Market capitalization of the company, segment and market as a whole
PMN - Market capitalization of the company PMN
ProMIS Neurosciences' market capitalization dynamics are a bet on a new approach to treating Alzheimer's disease. This biotech company's stock price reflects investor hopes for its ability to create antibodies targeting toxic forms of proteins. Its volatility reflects the market's assessment of this high-risk, yet potentially revolutionary, science.
PMN - Share of the company's market capitalization PMN within the market segment - Pharma neurology
ProMIS Neurosciences develops targeted therapeutics for the treatment of neurodegenerative diseases such as Alzheimer's. Its market share is based on its unique approach to detecting and targeting toxic forms of proteins. The chart shows investor valuations of its scientific platform.
Market capitalization of the market segment - Pharma neurology
ProMIS Neurosciences develops targeted drugs for the treatment of neurodegenerative diseases such as Alzheimer's. The chart below shows the market capitalization of the neuroscience sector. Its dynamics reflect the enormous hopes and equally significant risks in finding a cure for these devastating illnesses.
Market capitalization of all companies included in a broad market index - GURU.Markets
ProMIS Neurosciences develops drugs targeting toxic beta-amyloid oligomers, which are believed to be the cause of Alzheimer's disease. Its market capitalization is a bet on this scientific approach. The chart below shows the weight of companies pursuing a cure for this disease.
Book value capitalization of the company, segment and market as a whole
PMN - Book value capitalization of the company PMN
ProMIS Neurosciences is founded on a scientific platform for combating neurodegenerative diseases. The company's book value reflects its patents for technology for detecting and targeting misfolded proteins that cause Alzheimer's and other diseases, as well as its R&D capital. The chart below shows the financial basis for this cutting-edge research.
PMN - Share of the company's book capitalization PMN within the market segment - Pharma neurology
ProMIS Neurosciences relies on its R&D labs to develop treatments for neurodegenerative diseases. The S_BCap_Seg graph shows its share of scientific infrastructure, reflecting its focus on research.
Market segment balance sheet capitalization - Pharma neurology
ProMIS Neurosciences develops therapies for neurodegenerative diseases such as Alzheimer's. Its assets are scientific data and patents. The chart shows that its balance sheet is virtually devoid of tangible assets, which is typical for a research-focused biotech company.
Book value of all companies included in the broad market index - GURU.Markets
ProMIS Neurosciences' assets comprise a scientific platform for combating Alzheimer's disease. The company's book value reflects its R&D laboratories and the rights to the technology that enables the creation of antibodies that selectively attack toxic forms of beta-amyloid. This provides the foundation for the development of a more precise and safer drug.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - PMN
ProMIS Neurosciences develops antibodies to treat neurodegenerative diseases such as Alzheimer's. The company's book value is derived from cash reserves. Its market capitalization is a pure bet on the success of its unique scientific approach to targeting toxic proteins in the brain.
Market to book capitalization ratio in a market segment - Pharma neurology
ProMIS Neurosciences develops therapies for neurodegenerative diseases such as Alzheimer's. It's an early-stage biotech. The chart shows how the market values its unique scientific approach, offering a premium to its book value, which is primarily comprised of cash.
Market to book capitalization ratio for the market as a whole
ProMIS Neurosciences develops drugs to treat neurodegenerative diseases such as Alzheimer's. Its valuation is based on the potential of its scientific platform. The chart demonstrates how the market valuation reflects investors' faith in scientific breakthroughs, creating a huge gap with the book value, as is the case with many biotechs.
Debts of the company, segment and market as a whole
PMN - Company debts PMN
ProMIS Neurosciences, a company developing Alzheimer's therapy, uses debt to fund its expensive research. This chart shows the capital raised for the preclinical and early clinical development of its candidates. This is a long-term, high-risk bet on solving one of the most complex medical problems.
Market segment debts - Pharma neurology
ProMIS Neurosciences is an early-stage biotech company focused on developing therapies for neurodegenerative diseases such as Alzheimer's. Research in this area is extremely expensive and risky, and success is not guaranteed. This graph reflects its complete reliance on equity capital to fund its research.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio PMN
ProMIS Neurosciences develops treatments for neurodegenerative diseases such as Alzheimer's. This chart shows its financial strategy. In this highly complex field of medicine, where decades of research can yield no results, raising debt is an extremely risky move, signaling a high stake in a scientific breakthrough.
Market segment debt to market segment book capitalization - Pharma neurology
ProMIS Neurosciences is a biotech company developing treatments for neurodegenerative diseases such as Alzheimer's. This chart, for the pharmaceutical sector, illustrates how the industry funds long and risky research. It provides context for assessing the company's financial strategy in one of the most complex areas of medicine.
Debt to book value of all companies in the market
ProMIS Neurosciences develops therapeutic treatments for neurodegenerative diseases such as Alzheimer's by targeting toxic proteins. The company's debt-to-book ratio reflects investors' willingness to finance long-term, high-risk biotech projects, which is vital to advancing ProMIS's research.
P/E of the company, segment and market as a whole
P/E - PMN
ProMIS Neurosciences develops antibodies for targeted therapy of neurodegenerative diseases such as Alzheimer's by targeting toxic forms of proteins. This chart reflects its belief in its rigorous scientific approach. Its value indicates the degree of risk investors are willing to take in the hope that the company's technology will be more effective and safer than its competitors.
P/E of the market segment - Pharma neurology
ProMIS Neurosciences, like other biotechs, operates in a sector with high expectations. This chart shows the average P/E for this industry. Comparing the company's P/E to this benchmark allows us to understand how highly the market values its unique approach to treating Alzheimer's disease compared to numerous other developments in this complex field.
P/E of the market as a whole
ProMIS Neurosciences develops therapeutic antibodies for the treatment of neurodegenerative diseases such as Alzheimer's by targeting misfolded proteins. This chart illustrates the risk appetite in biotech. The company's valuation is based almost entirely on the hope that its unique scientific approach will lead to a breakthrough in one of the most complex areas of medicine.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company PMN
ProMIS Neurosciences develops targeted therapies for the treatment of neurodegenerative diseases such as Alzheimer's. The chart reflects speculative revenue expectations. These expectations are entirely dependent on the success of preclinical and clinical trials, which is an extremely risky but potentially highly profitable area.
%20P%2FE%20PMN&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-PMN&v=1772554092436 "Chart of the company's future (projected) P/E PMN")
Future (projected) P/E of the market segment - Pharma neurology
ProMIS Neurosciences develops targeted therapeutics for neurodegenerative diseases such as Alzheimer's by targeting toxic forms of proteins. This chart shows its future profitability expectations, allowing us to assess how highly the market values its rigorous scientific approach.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20neurology&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-neurology&v=1772554092462 "Future (projected) P/E graph of the market segment - Pharma neurology")
Future (projected) P/E of the market as a whole
ProMIS Neurosciences is a biotech company developing antibodies to treat neurodegenerative diseases such as Alzheimer's. This is one of the most complex and risky areas in medicine. The company's valuation is not based on market forecasts, but rather a bet on a scientific breakthrough.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772554092464 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit PMN
ProMIS Neurosciences is a biotech company developing therapeutic antibodies to treat neurodegenerative diseases such as Alzheimer's by targeting toxic forms of proteins. Being in the preclinical stage, it incurs significant R&D expenditures. This chart reflects its investment in a precision approach to drug development for brain diseases.
Profit of companies in the market segment - Pharma neurology
ProMIS Neurosciences is a biotech company developing targeted therapies for neurodegenerative diseases such as Alzheimer's. This chart shows the profitability of the neuroscience pharmaceutical sector. Being in the early stages of research, the company is not profitable, but its unique approach to antibody development could lead to breakthroughs in the treatment of these complex diseases.
Overall market profit
ProMIS Neurosciences is a biotech company developing treatments for neurodegenerative diseases such as Alzheimer's. Its valuation is determined by progress in clinical trials. Against the backdrop of general economic cycles, illustrated by this chart, ProMIS is working to solve one of the most complex problems in medicine, where success is not dependent on the market.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company PMN
ProMIS Neurosciences develops therapeutic approaches to treat neurodegenerative diseases such as Alzheimer's by targeting toxic forms of proteins. This chart reflects analysts' long-term, high-risk expectations. It demonstrates the market's faith in the company's unique scientific approach in one of the most complex areas of medicine.
%20profit%20of%20the%20company%20PMN&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-PMN&v=1772554092503 "Graph of future (projected) profit of the company PMN")
Future (predicted) profit of companies in the market segment - Pharma neurology
ProMIS Neurosciences, Inc. is a biotech company developing targeted therapies for the treatment of neurodegenerative diseases such as Alzheimer's. This chart shows profitability projections for the neuroscience pharmaceutical segment, reflecting high expectations for breakthroughs in the treatment of these complex diseases.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20neurology&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-neurology&v=1772554092529 "Graph of future (predicted) profits of companies in a market segment - Pharma neurology")
Future (predicted) profit of the market as a whole
ProMIS Neurosciences develops drugs for neurodegenerative diseases such as Alzheimer's. For a company in the research stage, the market profit forecast is an indicator of investors' risk appetite. An optimistic forecast, visible on the chart, facilitates attracting multimillion-dollar investments for long-term clinical trials.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772554092569 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - PMN
ProMIS Neurosciences is a biotech company developing therapies for neurodegenerative diseases such as Alzheimer's. Being in the research stage, it has no revenue. The P/S will only become relevant after successful clinical trials and demonstrate market confidence in its scientific approach.
P/S market segment - Pharma neurology
ProMIS Neurosciences develops therapeutic approaches targeting toxic forms of proteins that cause neurodegenerative diseases such as Alzheimer's. Being in the early stages, their evaluation depends entirely on scientific potential. This graph reflects the market's enormous hopes for a breakthrough in the treatment of these complex diseases.
P/S of the market as a whole
ProMIS Neurosciences develops therapeutic approaches to treating neurodegenerative diseases such as Alzheimer's by targeting toxic proteins. The company has no revenue, and its valuation represents a hope for a breakthrough in one of the most complex areas of medicine. This chart, based on actual revenue, highlights the high risk and potential of such investments.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company PMN
ProMIS Neurosciences develops targeted therapies for neurodegenerative diseases such as Alzheimer's, focusing on toxic forms of proteins. This chart reflects investor expectations for future revenue from these highly specific antibodies, betting on a new approach to combating one of the most challenging diseases.
%20P%2FS%20PMN&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-PMN&v=1772554092768 "The graph of the company's future (projected) P/S PMN")
Future (projected) P/S of the market segment - Pharma neurology
ProMIS Neurosciences, Inc. is a biotech company developing precision treatments for neurodegenerative diseases such as Alzheimer's. This chart shows how the market views the future potential of its unique scientific approach. It compares it to other companies in the neuroscience sector, reflecting the high hopes for breakthroughs in the treatment of these complex diseases.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20neurology&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-neurology&v=1772554092782 "Future (projected) P/S market segment graph - Pharma neurology")
Future (projected) P/S of the market as a whole
ProMIS Neurosciences develops therapeutic antibodies to treat neurodegenerative diseases such as Alzheimer's by targeting toxic forms of proteins. This chart shows overall market revenue expectations, and PMN exemplifies how the enormous expectations surrounding Alzheimer's treatments are impacting biotech company valuations.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772554092788 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales PMN
ProMIS Neurosciences is a clinical-stage biotechnology company developing therapies for neurodegenerative diseases such as Alzheimer's. The company currently has no approved products, so sales revenue is not included in this chart. The company is funded by investor capital.
Sales of companies in the market segment - Pharma neurology
ProMIS Neurosciences is a biotech company developing therapies for neurodegenerative diseases such as Alzheimer's. At this stage, its revenue, if any, may be derived from partnerships. This chart shows the financial flows supporting its long-term research.
Overall market sales
ProMIS Neurosciences is a biopharmaceutical company developing treatments for neurodegenerative diseases such as Alzheimer's. The need for such drugs is enormous and unaffected by the economic climate. This timeline is not a factor for ProMIS, whose success depends solely on scientific breakthroughs in this complex field.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company PMN
ProMIS Neurosciences is a clinical-stage company developing targeted therapies for neurodegenerative diseases such as Alzheimer's. Its revenue forecast is entirely dependent on research success. This chart shows analysts' speculative expectations for its scientific breakthroughs in this complex field.
%20sales%20of%20the%20company%20PMN&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-PMN&v=1772554092887 "Schedule of future (projected) sales of the company PMN")
Future (projected) sales of companies in the market segment - Pharma neurology
ProMIS Neurosciences develops precision treatments for neurodegenerative diseases such as Alzheimer's. This chart shows projected revenue for the entire neuroscience segment. It allows analysts to assess whether they see growth potential in this complex yet socially significant market, which is important for the future commercial success of ProMIS's developments.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20neurology&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-neurology&v=1772554092915 "Schedule of future (projected) sales of companies in the market segment - Pharma neurology")
Future (projected) sales of the market as a whole
ProMIS Neurosciences is a biotech company developing therapies for neurodegenerative diseases such as Alzheimer's. Its future depends on the success of clinical trials. This graph of general market expectations does not directly impact demand, but reflects the investment climate, which is critical for raising funds for long-term and risky R&D projects.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772554092949 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality PMN
ProMIS Neurosciences is a biopharmaceutical company developing treatments for neurodegenerative diseases such as Alzheimer's. This chart reflects the company's current status in preclinical and early clinical trials. It also shows the company's investment in research, the success of which determines its future.
Market segment marginality - Pharma neurology
ProMIS Neurosciences is a biotech company developing therapeutic antibodies for the treatment of neurodegenerative diseases such as Alzheimer's. This chart shows the average profitability in the neuroscience sector. It serves as a benchmark for understanding the potential commercial value of ProMIS's developments should they achieve clinical success in this challenging market.
Market marginality as a whole
ProMIS Neurosciences develops therapeutic approaches to treat neurodegenerative diseases such as Alzheimer's. This is one of the most complex and risky areas in pharmaceuticals. This total profitability chart shows the success of existing businesses, while ProMIS operates at the cutting edge of science, where the costs of failure and success are equally high.
Employees in the company, segment and market as a whole
Number of employees in the company PMN
ProMIS Neurosciences is a biotech company developing therapies for Alzheimer's disease. Its small team of scientists uses a unique platform to create highly precise antibodies. This graph illustrates how a small yet scientifically advanced group can address one of the most complex medical challenges.
Share of the company's employees PMN within the market segment - Pharma neurology
ProMIS Neurosciences is a biotech company developing precision treatments for neurodegenerative diseases such as Alzheimer's. This chart highlights its cutting-edge scientific approach. It illustrates the proportion of neuroscientists and computational biologists who use ProMIS's unique platform for creating antibodies against toxic proteins.
Number of employees in the market segment - Pharma neurology
ProMIS Neurosciences develops targeted therapeutics for the treatment of neurodegenerative diseases such as Alzheimer's. This chart illustrates employment in neurological pharmaceuticals. The growing number of scientists in this field reflects the enormous effort and investment devoted to finding effective treatments for these devastating diseases.
Number of employees in the market as a whole
ProMIS Neurosciences, Inc. is a biotech company developing treatments for neurodegenerative diseases such as Alzheimer's. This is one of the most complex and important areas in medicine. This chart shows overall employment, and investments in such companies indicate long-term trends in healthcare.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company PMN (PMN)
ProMIS Neurosciences is a biotech company focused on neurodegenerative diseases. Its value reflects the hope for a breakthrough in Alzheimer's treatment. This chart illustrates the enormous value the market places on the company's scientific platform. Every employee is part of a multi-billion-dollar bet to defeat the disease.
%20of%20the%20company%20PMN%20(PMN)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-PMN-PMN&v=1772554093027 "Chart of market capitalization per employee (in thousands of dollars) of the company PMN (PMN)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma neurology
ProMIS Neurosciences is developing a therapy for Alzheimer's disease. It's a high-risk biotech. Its per-employee market cap is pure speculation on the success of clinical trials. Its sky-high valuations, compared to average valuations, reflect the company's enormous potential market and investors' hopes for a scientific breakthrough from a small team.
%20by%20market%20segment%20-%20Pharma%20neurology&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-neurology&v=1772554093030 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma neurology")
Market capitalization per employee (in thousands of dollars) for the overall market
ProMIS Neurosciences is a biotech company developing targeted therapies for the treatment of neurodegenerative diseases such as Alzheimer's. This is one of the most complex areas in medicine. This chart reflects the enormous expectations investors have for the ability of a small team of scientists to create a breakthrough in the treatment of these devastating diseases.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772554093038 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company PMN (PMN)
ProMIS Neurosciences is a preclinical biotech company focused on treating neurodegenerative diseases like Alzheimer's. This is pure science. This deeply negative graph shows how much capital is spent on each scientist trying to find the key to curing one of the most complex diseases.
%20Chart%20PMN%20(PMN)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-PMN-PMN&v=1772554093069 "Company Profit Per Employee (in thousands of dollars) Chart PMN (PMN)")
Profit per employee (in thousands of dollars) in the market segment - Pharma neurology
ProMIS Neurosciences develops therapeutic antibodies for the treatment of neurodegenerative diseases such as Alzheimer's by targeting toxic protein oligomers. This graph highlights the potential value of their precision scientific approach. It illustrates the enormous profit potential of a successful drug in this field, developed by a small team of leading scientists.
%20in%20the%20market%20segment%20-%20Pharma%20neurology&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-neurology&v=1772554093090 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma neurology")
Profit per employee (in thousands of dollars) for the market as a whole
ProMIS Neurosciences is a biotech company developing therapies for neurodegenerative diseases such as Alzheimer's. At this R&D stage, the chart reflects the "cost" of research. It shows how much the company invests in its research team per employee to create potentially breakthrough treatments.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772554093097 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee PMN (PMN)
ProMIS Neurosciences is an early-stage biotech company developing treatments for neurodegenerative diseases. This graph, showing zero revenue per employee, is typical for the sector. It reflects the research phase. Clinical success could lead to a huge market cap and future growth.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-PMN-PMN&v=1772554093098 "Sales chart per company employee PMN (PMN)")
Sales per employee in the market segment - Pharma neurology
ProMIS Neurosciences (PMN) is a biotech company developing treatments for neurodegenerative diseases, such as Alzheimer's, by targeting toxic proteins. This chart shows the average revenue per employee in the pharmaceutical segment. ProMIS is in the R&D stage and has no commercial sales. Comparison with the benchmark highlights their focus on science rather than current productivity.
Sales per employee for the market as a whole
ProMIS Neurosciences (PMN) is an early-stage biotech company specializing in neurodegenerative diseases (Alzheimer's). There is no revenue. This metric is irrelevant. The company's entire value lies in its scientific hypotheses and preclinical data. This is a venture bet on a scientific breakthrough.
Short shares by company, segment and market as a whole
Shares shorted by company PMN (PMN)
ProMIS Neurosciences is a biotech company trying to develop a treatment for Alzheimer's disease. It's a "graveyard" for pharmaceutical companies. This chart shows the odds on inevitable failure. "Bears" are confident that the company, like hundreds of others before it, will fail to prove the effectiveness of its drug against this complex disease.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-PMN-PMN&v=1772554093125 "Short Shares Chart for the Company PMN (PMN)")
Shares shorted by market segment - Pharma neurology
ProMIS Neurosciences (PMN) is another company trying to combat Alzheimer's disease by targeting toxic proteins (amyloids). This chart shows widespread pessimism in the neuroscience sector. The surge in shorts across the sector is a bet that PMN, like hundreds before it, will fail clinical trials. Investors distrust the "amyloid hypothesis" and consider the entire sector a "graveyard" for capital.
Shares shorted by the overall market
ProMIS Neurosciences is developing a therapy targeting the toxic proteins that cause Alzheimer's disease. It's the "holy grail" of biotech. This chart measures overall fear. When investors are afraid, they're reluctant to bet on the riskiest bets. The "graveyard" of Alzheimer's drug trials is vast. During periods of panic, the risk of PMN failure seems almost certain.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator PMN (PMN)
ProMIS Neurosciences (PMN) is a biotech company developing treatments for neurodegenerative diseases like Alzheimer's. This is the "holy grail" of biotech. This chart measures the rate of change in sentiment. It shows when enthusiasm (above 70) or disappointment (below 30) about clinical trial data reaches extremes.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-PMN-PMN&v=1772554093338 "RSI 14 indicator chart for the company's stock PMN (PMN)")
RSI 14 Market Segment - Pharma neurology
ProMIS (PMN) is a biotech company targeting misfolded proteins that are the cause of neurodegenerative diseases like Alzheimer's. This chart measures the pulse of the Pharma/Neurology sector. It helps distinguish PMN's performance from general overheating or overselling in the biotech sector.
RSI 14 for the overall market
ProMIS Neurosciences (PMN) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria offers the potential to easily raise hundreds of millions of dollars for research. Market panic risks running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast PMN (PMN)
ProMIS Neurosciences is a biotech company developing targeted therapies for the treatment of neurodegenerative diseases, primarily Alzheimer's disease. This chart shows the speculative average 12-month price target from analysts, which is almost entirely based on their assessment of the company's R&D portfolio.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-PMN-PMN&v=1772554093388 "A chart showing analyst consensus forecasts for the expected stock price. PMN (PMN)")
The difference between the consensus estimate and the actual stock price PMN (PMN)
ProMIS is a biotech company developing a targeted therapy for Alzheimer's disease, targeting only the "toxic" forms of the amyloid protein. This chart measures the gap between the current share price and the consensus target price. It shows the potential analysts see in this R&D approach.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-PMN-PMN&v=1772554093429 "A chart showing the difference between the consensus forecast and the actual stock price. PMN (PMN)")
Analyst consensus forecast for stock prices by market segment - Pharma neurology
ProMIS Neurosciences is a biotech company pursuing Alzheimer's disease. It develops antibodies that target the most toxic misfolded proteins in the brain. This chart shows general expectations for the neuroscience sector. It reflects whether experts believe a breakthrough in Alzheimer's treatment is possible or whether they consider the sector too risky.
Analysts' consensus forecast for the overall market share price
ProMIS Neurosciences is a biotech company specializing in developing antibodies to treat neurodegenerative diseases (Alzheimer's) by targeting "toxic" proteins. This chart shows the overall "risk appetite" in the market. For ProMIS, which operates in the most complex area of medicine, overall market optimism is critical to funding long-term, expensive trials.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index PMN
ProMIS Neurosciences is a clinical-stage biotech company focused on precision treatments for neurodegeneration (Alzheimer's). Their signature feature is that they don't target all amyloid, but only its toxic forms. This graph is a pure indicator of their R&D. Its dynamics depend entirely on their (very risky) clinical trial data.
AKIMA Market Segment Index - Pharma neurology
ProMIS Neurosciences (PMN) is a biopharmaceutical company developing targeted therapies for the treatment of neurodegenerative diseases, particularly Alzheimer's disease, by selectively targeting toxic beta-amyloids. The chart shows the average index for the segment, helping investors assess how PMN's risks in this highly complex field compare to the average.
The AKIM Index for the overall market
ProMIS Neurosciences is a biotech company developing antibodies targeting toxic oligomers in Alzheimer's and ALS. This chart, which reflects the market average, provides a macro backdrop. It helps assess how this speculative scientific story fits into the broader economic trends affecting neuroscience.
